NASDAQ:RANI Rani Therapeutics (RANI) Stock Price, News & Analysis $0.53 -0.01 (-0.94%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.52 -0.01 (-0.95%) As of 08/8/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Rani Therapeutics Stock (NASDAQ:RANI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Rani Therapeutics alerts:Sign Up Key Stats Today's Range$0.52▼$0.5450-Day Range$0.41▼$0.7052-Week Range$0.39▼$3.75Volume461,954 shsAverage Volume4.76 million shsMarket Capitalization$33.37 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingBuy Company Overview Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California. Read More Rani Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreRANI MarketRank™: Rani Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 714th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingRani Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRani Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Rani Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Rani Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rani Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rani Therapeutics is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRani Therapeutics has a P/B Ratio of 8.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.83% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Rani Therapeutics has recently increased by 88.62%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRani Therapeutics does not currently pay a dividend.Dividend GrowthRani Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted29.83% of the float of Rani Therapeutics has been sold short.Short Interest Ratio / Days to CoverRani Therapeutics has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Rani Therapeutics has recently increased by 88.62%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.80 News SentimentRani Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Rani Therapeutics this week, compared to 1 article on an average week.Search Interest9 people have searched for RANI on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows2 people have added Rani Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Rani Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders45.08% of the stock of Rani Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.19% of the stock of Rani Therapeutics is held by institutions.Read more about Rani Therapeutics' insider trading history. Receive RANI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RANI Stock News HeadlinesRani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate UpdateAugust 7 at 4:18 PM | globenewswire.comRani Therapeutics Holdings, Inc. (RANI) - Yahoo FinanceJuly 18, 2025 | finance.yahoo.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!). | Weiss Ratings (Ad)Rani Therapeutics Shares Drop Sharply Following $3 Million Direct Offering AnnouncementJuly 15, 2025 | msn.comRani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct OfferingJuly 15, 2025 | globenewswire.comRani Therapeutics Shares Surge After ENDO 2025 Presentation AnnouncementJuly 14, 2025 | msn.comRani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous DeliveryJuly 14, 2025 | globenewswire.comRani Therapeutics announces annual meeting resultsMay 30, 2025 | investing.comSee More Headlines RANI Stock Analysis - Frequently Asked Questions How have RANI shares performed this year? Rani Therapeutics' stock was trading at $1.37 at the start of the year. Since then, RANI stock has decreased by 61.5% and is now trading at $0.5280. How were Rani Therapeutics' earnings last quarter? Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) issued its quarterly earnings results on Thursday, August, 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. When did Rani Therapeutics IPO? Rani Therapeutics (RANI) raised $100 million in an IPO on Friday, July 30th 2021. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. Who are Rani Therapeutics' major shareholders? Top institutional shareholders of Rani Therapeutics include Janney Montgomery Scott LLC (0.09%) and Well Done LLC (0.09%). Insiders that own company stock include South Cone Investments Limited, Talat Imran, Mir A Imran, Kate Mckinley and Cortes Isidoro Alfonso Quiroga. View institutional ownership trends. How do I buy shares of Rani Therapeutics? Shares of RANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Rani Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rani Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), Honeywell International (HON), CrowdStrike (CRWD), Cisco Systems (CSCO), Intel (INTC) and CocaCola (KO). Company Calendar Last Earnings8/07/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RANI CIK1856725 Webwww.ranitherapeutics.com Phone408-457-3700FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Rani Therapeutics$7.33 High Price Target$9.00 Low Price Target$4.00 Potential Upside/Downside+1,288.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$30.02 million Net MarginsN/A Pretax Margin-4,545.25% Return on Equity-2,272.39% Return on Assets-85.38% Debt Debt-to-Equity Ratio2.75 Current Ratio0.88 Quick Ratio0.88 Sales & Book Value Annual Sales$1.03 million Price / Sales32.40 Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book8.80Miscellaneous Outstanding Shares63,210,000Free Float34,714,000Market Cap$33.37 million OptionableOptionable Beta-0.02 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RANI) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.